Charles Kent Ltd ePortfolio
Download as PPTX, PDF
0 likes577 views
The document provides examples of diagrams and figures before and after being redrawn by Charles Kent Ltd, a visual communications specialist, for use in posters, presentations, and manuscripts, showing their work in restructuring and standardizing complex scientific diagrams to be more clear and reader-friendly. It also includes examples of their work redrawing graphs and charts from published studies to improve visual presentation. The document demonstrates Charles Kent Ltd's expertise in figure layout and redrawing for optimized communication of scientific concepts, data, and study results.
Charles Kent Ltd ePortfolio
- 2. Charles Kent Ltd Visual Communications Specialist
- 3. Diagrams
- 4. 京艶韓看姻艶
- 5. After ANP Hypertrophic gene program Ca2+ Ca2+ Calcineurin NFAT NFATGATA CaMKII PKG RGS2 Angiotensin II TRPC 3/6 GPCR GC-A TRRC MCP IP3 NFAT P P PLC RGS2 Goq GTP
- 6. 京艶韓看姻艶 Pre-launch Launch Post-Launch Online resource for oncologists and pathologists a therapy area portal approach Brand website New MOAfor EGFR-TKI Plugging into the established communication networks Congress activities EGFRtesting app Augmented reality/ interactive sales aids Patient portal Materials produced in conjunction with patient organisations Multichannel integration:Our approach is to ensure activities are integrated into the communication strategy to enable maximum reach with key stakeholders with consistent messaging across all channels Booth materials
- 7. 粥韓岳艶姻 PRE-LAUNCH LAUNCH POST-LAUNCH Congress activities Plugging into the established communication networks Patient portal Online resource for oncologists and pathologists a therapy area portal approach New MOA for EGFR-TKI Materials produced in conjunction with patient organisationsBooth materials Augmented reality/ interactive sales aids Brand website EGFR testing app > Multichannel integration: Our approach is to ensure activities are integrated into the communication strategy to enable maximum reach with key stakeholders with consistent messaging across all channels
- 8. 京艶韓看姻艶 Induction +2842d post cycle 4, Maintenance 25m post cycle 4 Product A 375 mg/m2 IV Product A 375 mg/m2 IV Relapsed CD20+ iNHL Prior response >6 mo to last Product A rx ABC101 ( Product B ) 1000 mg IV ABC101 ( Product B ) 1000 mg IV 9 PD Discontinue Treatment CT/PET CT/PET CT CT CT CT 3m 6m 12m 18m CT 25m Randomized phase II trial comparing ABC101 (Product B) with product A in patients with relapsed CD20+ indolent B-cell NHL w1 w2 w3 w4 m2 m4 m6 m24 RANDOMIZATION EndofInduction EndofMaintenance
- 9. 粥韓岳艶姻 Relapsed CD20+ iNHL Prior response 6 mo to last product A rx Induction Maintenance Product A 375 mg/m2 IV Product A 375 mg/m2 IV ABC101 (Product B) 1000 mg IV ABC101 (Product B) 1000 mg IV End of induction End of maintenance +2842d post cycle 4 25m post cycle 4 CT/PET Randomization CT CT CT CT CTCT/PET 3m 6m 12m 18m 25m PD discontinue treatment Randomized phase II trial comparing ABC101 (Product B) with product A in patients with relapsed CD20+ indolent B-cell NHL w1 w2 w3 w4 m2 m4 m6 m24
- 10. 京艶韓看姻艶
- 11. 粥韓岳艶姻 Standardised measures to track/quantify symptoms (eg ACT, ASQ, CAT) Peak flow diary results, spirometry results/pulmonary function tests (FEV1) If patient presents to HCP (outside of a routine consultation) this is first indicator that they may not be controlled Basic questions about symptoms experienced and exposure to triggers (many have a battery of questions they use) Symptom quantification Objective clinical measures Symptom report / questioning Patient presentation ACT and ASQ are useful but we dont go through each of them, just pick specific questions. SPECIALIST, Dublin Ultimately it is a clinical syndrome so we are looking at that rather than lab measures to monitor. SPECIALIST, Dublin If they are not seeing us we hope they are controlled. NURSE, Manchester Less used
- 12. Layout
- 17. Figure Redrawing for Posters, Presentations & Manuscripts
- 18. 京艶韓看姻艶
- 19. 粥韓岳艶姻LVEDV(ml) 0 100 200 300 LVESV(ml) 0 100 200 SV(ml) 0 40 60 80 20 * EF(%) 0 20 40 60 TPR (dyne-sec-cm5) 0 2000 3000 ANF(pg/ml) 0 40 60 20 * * * * ** * * * * * ** 1000 * * Controls CHF Controls CHF Base 60 120 Base 60 120 Base 60 120 Base 60 120 Time (minutes) Time (minutes) ** * * * * ** * * ** * * * *
- 20. 京艶韓看姻艶 Comparator 1 Overall Survival Prior Platinum Exposure HR 1.23 (95% CI 0.45-6.78) RR: 12% (CP) vs 34% (TP) HR 1.23 (95% CI 0.45-6.78) RR: 12% (CP) vs 34% (TP) Prior Comparator A No Prior Comparator A Comparator A backbone Comparator A backbone Comparator B backbone Comparator B backbone
- 21. 粥韓岳艶姻 Comparator 1 Overall Survival Prior Platinum Exposure` Proportionsurviving Months on Study 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 0 2412 186 Prior Comparator A No Prior Comparator A Proportionsurviving Months on Study 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 0 2412 186 HR: 1.23 (95% CI 0.456.78) RR: 12% (CP) vs 34% (TP) HR: 1.23 (95% CI 0.456.78) RR: 12% (CP) vs 34% (TP) Comparator A Comparator B Alive 123 45 Dead 67 89 Total 112 345 Comparator A Comparator B Alive 123 45 Dead 67 89 Total 112 345
- 22. 京艶韓看姻艶
- 23. 粥韓岳艶姻SV(ml) 0 50 100 ANF(pg/ml) 0 60 20 180 280 180 280 Untreated CEI Base 60 120 Volume Expansion
- 24. 京艶韓看姻艶
- 25. 粥韓岳艶姻
- 27. Advanced User: Adobe Illustrator CC Adobe Photoshop CC Adobe InDesign CC Adobe Acrobat Microsoft Powerpoint (2013) Microsoft Word (2013) Microsoft Excel (2013) Quark Express